Goblet cell adenocarcinoma (GCA) is a rare and histologically distinct subtype of appendix cancer. When GCA spreads to involve the peritoneum exclusively, its management follows a specific protocol that differs from standard colorectal oncology pathways.

Clinical scenario

GCA — also historically referred to as goblet cell carcinoid — accounts for approximately 14–19% of primary appendix cancers. Unlike classical appendix neuroendocrine tumors, GCA shares immunohistochemical and biologic characteristics with adenocarcinoma, which directly shapes the therapeutic strategy, particularly when peritoneal-only metastatic disease is present.

Treatment approach

For GCA patients with peritoneal-only metastatic disease, the protocol involves a surgical cytoreductive approach combined with intraperitoneal chemotherapy. The complete regimen, eligibility criteria, and delivery details are available in the full structured protocol.

References

DOI: 10.1055/s-0035-1564433

Goblet cell adenocarcinoma (GCA), also commonly referred to as "goblet cell carcinoid," is a rare tumor type accounting for approximately 14 to 19% of primary appendix cancers.
Recent studies have shown that GCAs are actually closer to adenocarcinoma than neuroendocrine carcinoma in terms of both immunohistochemical profile and biologic behavior.
For GCA patients presenting with peritoneal-only metastatic disease, evidence suggests there is a role for cytoreduction and IPC.
In a recent report of 45 patients with peritoneal-only metastasis of GCA undergoing evaluation for cytoreduction and HIPEC, complete cytoreduction was achieved in 71% of cases and HIPEC (with MMC or oxaliplatin) was administered in 80%.

View source ↗

Treatment of Adenocarcinoma of the Appendix in Goblet Cell Adenocarcinoma

References